← Eichor
Condition: Grade Iii Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Grade Iii Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3 · 33 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06809322A Phase 2 Study of HX301 in Patients with High-grade Giloma
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06703255Combination Therapy for the Treatment of Diffuse Midline Gliomas
Phase 2 · 32 location(s) · University of California, San Francisco · NCT05009992Implantable Microdevice In Primary Brain Tumors
EARLY_Phase 1 · 1 location(s) · Oliver Jonas · NCT04135807Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT05859334ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
NA · 2 location(s) · Medical University of Warsaw · NCT07488754Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06964737Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
Phase N/A · 1 location(s) · NanoAlvand · NCT07675070Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Phase 1 · 1 location(s) · Susan Chang · NCT04540107SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05565118Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Phase 2 · 1 location(s) · Marzieh Ebrahimi · NCT06687681Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · 82 location(s) · Alliance for Clinical Trials in Oncology · NCT07215910A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140Fluorescence Enhanced Stereotactic Surgery (FESS)
Phase N/A · 1 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07286903Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescen
Phase 3 · 2 location(s) · Lee's Pharmaceutical Limited · NCT06160492The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Phase N/A · 8 location(s) · Jasper Gerritsen · NCT06118723Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Tr
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04479696A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Rec
Phase 1 · 3 location(s) · Neuregen Therapeutics Co., Ltd. · NCT07710690Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
EARLY_Phase 1 · 1 location(s) · Eben Rosenthal · NCT07210632Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
NA · 2 location(s) · Medical University of Warsaw · NCT06975332Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.